111 (NASDAQ:YI) Given “Sell (E+)” Rating at Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of 111 (NASDAQ:YI) in a report published on Tuesday morning,Weiss Ratings reports.

111 Price Performance

Shares of YI stock opened at $6.69 on Tuesday. 111 has a one year low of $4.15 and a one year high of $14.10. The company’s fifty day moving average price is $8.19 and its 200-day moving average price is $7.51. The company has a market capitalization of $57.21 million, a price-to-earnings ratio of -1.67 and a beta of 0.57.

111 (NASDAQ:YI) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter. The business had revenue of $527.14 million during the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its holdings in shares of 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock valued at $191,000 after purchasing an additional 305,339 shares during the last quarter. Napean Trading & Investment Co Singapore PTE Ltd bought a new stake in shares of 111 in the fourth quarter worth about $245,000. Finally, FIL Ltd purchased a new stake in shares of 111 in the fourth quarter worth about $450,000. 21.32% of the stock is currently owned by institutional investors.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.